- Investing Ideas
- Swiss Biotech Stocks
Swiss Biotech Stocks
Results
17
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
17 companies
Novartis
Market Cap: CHF 216.7b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 119.04
7D
4.9%
1Y
22.7%
Galderma Group
Market Cap: CHF 38.8b
Operates as a dermatology company worldwide.
GALD
CHF 166.65
7D
2.6%
1Y
46.4%
Lonza Group
Market Cap: CHF 34.6b
Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 499.00
7D
2.1%
1Y
-13.5%
Roche Holding
Market Cap: CHF 34.6b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 323.90
7D
3.9%
1Y
20.0%
Sandoz Group
Market Cap: CHF 28.0b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 66.02
7D
5.0%
1Y
54.7%
Bachem Holding
Market Cap: CHF 5.1b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 67.00
7D
-1.3%
1Y
21.2%
Siegfried Holding
Market Cap: CHF 3.4b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 76.80
7D
-1.5%
1Y
-20.4%
Tecan Group
Market Cap: CHF 1.9b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 153.60
7D
-2.1%
1Y
-11.2%
PolyPeptide Group
Market Cap: CHF 1.2b
Operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally.
PPGN
CHF 33.80
7D
-9.1%
1Y
57.2%
Cosmo
Market Cap: CHF 1.1b
A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
COPN
CHF 70.50
7D
-1.9%
1Y
17.1%
Kuros Biosciences
Market Cap: CHF 773.0m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 20.40
7D
8.2%
1Y
-25.3%
Basilea Pharmaceutica
Market Cap: CHF 608.6m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 48.60
7D
-2.5%
1Y
-6.4%
Newron Pharmaceuticals
Market Cap: CHF 247.2m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 11.74
7D
-3.1%
1Y
54.5%
Xlife Sciences
Market Cap: CHF 129.4m
Focuses on the development and commercialization of research projects in the life sciences sector.
XLS
CHF 22.20
7D
-7.5%
1Y
8.3%
Curatis Holding
Market Cap: CHF 118.1m
Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.
CURN
CHF 22.50
7D
1.8%
1Y
87.5%
Molecular Partners
Market Cap: CHF 114.4m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 3.06
7D
-1.9%
1Y
6.8%
MindMaze Therapeutics Holding
Market Cap: CHF 50.7m
Operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally.
MMTX
CHF 0.31
7D
-13.9%
1Y
n/a